<unk>  is used along with diet and exercise to improve glycemic control in adults with type 2 diabetes and to reduce the risk of hospitalization for heart failure among adults with type 2 diabetes and known cardiovascular disease or other risk factors. It appears more useful than empagliflozin. In addition,<unk>  is indicated for the treatment of adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. It is also indicated to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression. In the European Union it is indicated in adults: * for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: * as monotherapy when metformin is considered inappropriate due to intolerance; * in addition to other medicinal products for the treatment of type 2 diabetes; * for the treatment of heart failure with reduced ejection fraction. In November 2021, the European Medicines Agency (EMA) stated that<unk>  should no longer be used to treat type 1 diabetes.
Dapagliflozin
Canagliflozin
Linagliptin
Empagliflozin
Sotagliflozin
Liraglutide
Vildagliptin
Pioglitazone